Plain-English translation of NCT05587894 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether people with weakened immune systems who have mild COVID-19 can recover better by taking nirmatrelvir/ritonavir — sometimes combined with another medication called remdesivir — for either 5 or 10 days. Researchers want to find out if using two medications together, or using the medication for longer, helps clear the virus from the body more quickly.
People with weakened immune systems often have a harder time fighting off COVID-19 on their own, and the virus can linger in their bodies longer. This study is trying to figure out if stronger or longer treatment can help these patients recover faster and reduce the risk of serious illness.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to one of four groups: taking one medication for 5 days, one medication for 10 days, two medications for 5 days, or two medications for 10 days. You'll take your assigned treatment at home and return for visits to have your nasal swab tested to check if the virus is clearing from your body. The study takes place in France and Switzerland, and your main follow-up visit will be around day 10.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France